Modality
Degrader
MOA
FXIai
Target
AuroraA
Pathway
Checkpoint
Breast CaNMOSDHCC
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
May 2020
→ Dec 2026
Phase 2Current
NCT08328151
2,644 pts·Breast Ca
2020-05→2026-12·Terminated
NCT05934997
324 pts·NMOSD
2021-06→TBD·Recruiting
2,968 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-12-058mo awayPh3 Readout· Breast Ca
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2/3
Termina…
P2/3
Recruit…
Catalysts
Ph3 Readout
2026-12-05 · 8mo away
Breast Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08328151 | Phase 2/3 | Breast Ca | Terminated | 2644 | SeizFreq |
| NCT05934997 | Phase 2/3 | NMOSD | Recruiting | 324 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA |